Levetiracetam 1000 mg Under Fasting Conditions
Condition: Healthy
Intervention: Levetiracetam; Keppra®
Intervention description: 1000 mg Tablet; 1000 mg Tablet
Intervention MeSH terms: Levetiracetam
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 30.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Bioequivalence; Healthy Subjects

Summary:

      THe objective of this study is to compare the rate and extent of absorption of an
      investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the
      commercially available reference product under fasting conditions.
    

Eligibility criteria:

        Inclusion Criteria

        All subjects must satisfy the following criteria to be considered for study participation:

          -  Subject must be male or non-pregnant, non-breast-feeding female

          -  Subject must be at least 18 years of age

          -  Subject must have a Body Mass Index (BMI) between 19 and 30 kg/m2, inclusive, and body
             weight should be at least 50 kg (110 lbs)

          -  Female Subjects - not surgically sterile or at least two years postmenopausal - must
             agree to utilize one of the following forms of contraception, if sexually active with
             a male partner, from screening through completion of the study. Approved forms of
             contraception are abstinence, double barrier (condom with spermicide, diaphragm with
             spermicide), intra-uterine device (IUD), or vasectomized partner (6 months minimum
             since vasectomy).

          -  Subject must voluntarily consent to participate in this study and provide their
             written informed consent prior to the start of any study-specific procedures.

          -  Subject is willing and able to remain in the study unit for the entire duration of
             each confinement period and return for any outpatient visits.

        Exclusion Criteria

        Subjects may be excluded for any of the following:

          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
             neurologic, oncologic, or psychiatric disease or any other condition which, in the
             opinion of the Investigator would jeopardize the safety of the subject or the validity
             of the study results.

          -  Has a clinically significant abnormal finding on the physical exam, medical history,
             ECG or clinical laboratory results at screening.

          -  History or presence of allergic or adverse response to levetiracetam or related drugs.

          -  Has been on a significantly abnormal diet during the four weeks preceding the first
             dose of study medication.

          -  Has donated blood or plasma within 30 days prior to the first dose of study
             medication.

          -  Has participated in another clinical trial within 30 days prior to the first dose of
             study medication.

          -  Has used any over-the-counter (OTC) medication, including nutritional supplements,
             within 7 days prior to the first dose of study medication.

          -  Has used any prescription medication, including hormonal contraceptive or hormonal
             replacement therapy, within 14 days prior to the first dose of study medication.

          -  Has been treated with any known enzyme altering drugs such as barbiturates,
             phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first
             dose of study medication.

          -  Has smoked or used tobacco products within 90 days prior to the first dose of study
             medication.

          -  Subject has consumed alcohol, caffeine/xanthine, or grapefruit containing beverages
             and foods from 48 hours prior to the dose of study medication and throughout the
             sample collection period.

          -  Is a female with a positive pregnancy test result.

          -  Female who has used implanted or injected hormonal contraceptives anytime during the 6
             months prior to study start.

          -  Has an intolerance to venipuncture.

          -  Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,
             benzodiazepines, cocaine, cannabinoids, opiates)

          -  Has a history of drug or alcohol abuse.

          -  Has had a positive test for, or has been treated for hepatitis B, hepatitis C or HIV.